Novo Nordisk (NOV) Stock Price & Analysis

24 Followers

NOV Stock Chart & Stats

CHF 173.42CHF 0.00(0.00%)

At close: Nov 12 5:30 PM GMT+1

Day’s Range: CHF 173.23 - CHF 174.39
52-Week Range: CHF 173.23 - CHF 174.39
Previous Close: CHF 173.42
Volume: N/A
Average Volume (3M): 0
Market Cap: CHF 149.40B
Enterprise Value: CHF 1.21T
Total Cash (Recent Filing): CHF 41.55B
Total Debt (Recent Filing): CHF 118.72B
Price to Earnings (P/E): 10.8
Beta: N/A
Next Earnings: Feb 03, 2027 (Est.)
EPS Estimate: 0.56
Next Dividend Ex-Date: N/A
Dividend Yield: 3.97%

Novo Nordisk News

Novo Nordisk announces new real-world data from PLATINUM-Truveta, RHODIUM-2

Novo Nordisk (NVO) announced new real-world data from PLATINUM-Truveta and RHODIUM-2, which are two retrospective studies evaluating associations between semaglutide 2.4 mg once-weekly injection use versus those not initiating treatment

6d agoNVO NOV

Novo Nordisk price target raised to DKK 298 from DKK 296 at Citi

Citi raised the firm’s price target on Novo Nordisk (NVO) to DKK 298 from DKK 296 and keeps a Neutral rating on the shares. Published first on TheFly – the

1w agoNVO NOV

Morning Movers: Datadog declines following third quarter earnings

Stock futures are sharply higher as investors react to the Democrats’ sweep of the midterm elections, with the party winning control of both the House and Senate. The election results

1w agoAMD CAR

Moderately bullish activity in Novo Nordisk with shares down 0.31%

Moderately bullish activity in Novo Nordisk (NVO), with shares down 12c near $40.33. Options volume roughly in line with average with 32k contracts traded and calls leading puts for a

1w agoNVO NOV

Cboe data suggests bullish flow in Novo Nordisk with shares up 1.49%

Cboe data suggests bullish flow in Novo Nordisk (NVO), with shares up 58c, or 1.49%, near $39.73. Options volume more than double the daily average with 49k contracts traded and

1w agoNVO NOV

AbbVie Science Chief says interested in building out obesity assets

AbbVie (ABBV) Chief Scientific Officer Roopal Thakkar said on the company’s earnings call: “Yes, we continue to have interest to build out obesity assets. We are open to anything that

1w agoLLY NVO

Moderately bullish activity in Novo Nordisk with shares up 1.27%

Moderately bullish activity in Novo Nordisk (NVO), with shares up 48c, or 1.27%, near $38.77. Options volume roughly in line with average with 18k contracts traded and calls leading puts

2w agoNVO NOV

Moderately bullish activity in Novo Nordisk with shares up 0.24%

Moderately bullish activity in Novo Nordisk (NVO), with shares up 10c, or 0.24%, near $39.15. Options volume relatively light with 26k contracts traded and calls leading puts for a put/call

2w agoNVO NOV

FDA approves Novo Nordisk’s Awiqli for type 2 diabetes in kids 10 and older

The U.S. Food and Drug Administration has approved Awiqli injection, a long-acting insulin analog, as an adjunct to diet and exercise to improve glycemic control in pediatric patients aged 10

2w agoNVO NOV

Big Pharma’s Obesity Shopping Spree Is Moving Beyond GLP-1s. Palatin May Fit the Pattern (NASDAQ: PTN)

WSW, NY, October 21st, 2026, FinanceWire Recent acquisitions and licensing deals reveal what drugmakers want next: different biology, better dosing and treatments that can complement existing medicines. Palatin is developing

3w agoNVO PTN

Cboe data shows mixed options sentiment in Novo Nordisk with shares down 0.76%

Cboe data shows mixed options sentiment in Novo Nordisk (NVO), with shares down 30c near $38.53. Options volume roughly in line with average with 65k contracts traded and puts leading

3w agoNVO NOV

Novo Nordisk: Market Perform and $47 Price Target Maintained Amid Obesity Strength and Competitive Risks

Novo Nordisk, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Evan Seigerman from BMO Capital maintained a Hold rating on the stock and has a

1M agoNVO NOV

Novo Nordisk Kept at Hold as Analyst Maintains $47 Price Target Amid Strategic Uncertainty

BMO Capital analyst Evan Seigerman maintained a Hold rating on Novo Nordisk yesterday and set a price target of $47.00. Evan Seigerman has given his Hold rating due to a

1M agoNVO NOV

Entera is on the Cusp of the Trial That Could Unlock America’s Osteoporosis Drug Market (NASDAQ: ENTX)

WSW, NY, August 31st, 2026, FinanceWire The drugs that rebuild bone are locked inside a channel most patients never reach. Entera (NASDAQ:ENTX) is nearing the pivotal trial built to change

2M agoLLY NVO

NOV FAQ

What was Novo Nordisk’s price range in the past 12 months?

Novo Nordisk lowest stock price was CHF173.23 and its highest was CHF174.39 in the past 12 months.

What is Novo Nordisk’s market cap?

Novo Nordisk’s market cap is CHF149.40B.

When is Novo Nordisk’s upcoming earnings report date?

Novo Nordisk’s next earnings report is estimated for Feb 03, 2027 (not yet confirmed), which is in 82 days.

How were Novo Nordisk’s earnings last quarter?

Novo Nordisk released its earnings results on Nov 04, 2026. The company reported CHF0.714 earnings per share for the quarter, beating the consensus estimate of CHF0.586 by CHF0.128.

Is Novo Nordisk overvalued?

According to Wall Street analysts Novo Nordisk’s price is currently Overvalued.

Does Novo Nordisk pay dividends?

Novo Nordisk does not currently pay dividends.

What is Novo Nordisk’s EPS estimate?

Novo Nordisk’s EPS estimate is 0.56.

How many shares outstanding does Novo Nordisk have?

Novo Nordisk has 3,390,128,000 shares outstanding.

What happened to Novo Nordisk’s price movement after its last earnings report?

Novo Nordisk reported an EPS of CHF0.714 in its last earnings report, beating expectations of CHF0.586. Following the earnings report the stock price went same 0%.

Which hedge fund is a major shareholder of Novo Nordisk?

Currently, no hedge funds are holding shares in CH:NOV

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Novo Nordisk

Novo Nordisk A/S operates as a global healthcare enterprise, dedicated to the innovation, development, production, and commercialization of pharmaceutical solutions. Its business is primarily divided into two key segments: Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity Care segment offers a comprehensive portfolio of treatments for diabetes (including insulins, GLP-1 analogues, oral antidiabetic agents, and related delivery systems), obesity management, glucagon, medical needles, and other chronic conditions. The Rare Disease segment provides specialized medications for haemophilia, various blood disorders, endocrine imbalances, growth hormone deficiencies, and hormone replacement therapy. Additionally, the company engages in strategic alliances, including a partnership with Gilead Sciences, Inc., and conducts research focused on identifying cell-specific carriers for nucleic acid-based therapies. Established in 1923, Novo Nordisk A/S is headquartered in Bagsvaerd, Denmark.

Novo Nordisk (NOV) Earnings & Revenues

Historic Earnings Reports

NOV Stock 12 Month Forecast

Average Price Target

CHF35.60▼(-79.47% Downside)

Past 12 Months12 Month ForecastFeb2026Nov2026

HighCHF43.17

AverageCHF35.60

LowCHF27.50

Detailed Analyst Forecast >

Technical Analysis

Overall Consensus

Indicator	Bullish	Neutral	Bearish
Overall Consensus	4	5	8
Technical Analysis	4	0	1
Moving Averages	0	5	7

Technical Analysis >

Ownership Overview

0.01% Insiders
12.15% Mutual Funds
<0.01% Other Institutional Investors
75.07% Public Companies and Individual Investors

Detailed Ownership Overview >

Popular Stocks

Popular Stocks
Company	Price & Change	Follow
NVDANvidia
AAPLApple
MSFTMicrosoft

NOV Stock Chart & Stats

Novo Nordisk News

Novo Nordisk announces new real-world data from PLATINUM-Truveta, RHODIUM-2

Novo Nordisk price target raised to DKK 298 from DKK 296 at Citi

Morning Movers: Datadog declines following third quarter earnings

Moderately bullish activity in Novo Nordisk with shares down 0.31%

Cboe data suggests bullish flow in Novo Nordisk with shares up 1.49%

AbbVie Science Chief says interested in building out obesity assets

Moderately bullish activity in Novo Nordisk with shares up 1.27%

Moderately bullish activity in Novo Nordisk with shares up 0.24%

FDA approves Novo Nordisk’s Awiqli for type 2 diabetes in kids 10 and older

Big Pharma’s Obesity Shopping Spree Is Moving Beyond GLP-1s. Palatin May Fit the Pattern (NASDAQ: PTN)

Cboe data shows mixed options sentiment in Novo Nordisk with shares down 0.76%

Novo Nordisk: Market Perform and $47 Price Target Maintained Amid Obesity Strength and Competitive Risks

Novo Nordisk Kept at Hold as Analyst Maintains $47 Price Target Amid Strategic Uncertainty

Entera is on the Cusp of the Trial That Could Unlock America’s Osteoporosis Drug Market (NASDAQ: ENTX)

NOV FAQ

Company Description

Novo Nordisk

Novo Nordisk (NOV) Earnings & Revenues

NOV Stock 12 Month Forecast

Average Price Target

Technical Analysis

Overall Consensus

Ownership Overview

Popular Stocks

Become an Expert with TipRanks Premium